Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery (InsuLearn-SMA)

May 7, 2026 updated by: Melissa J. Schoelwer
To evaluate the safety and feasibility of a novel self-learning bolus calculator along with simplified meal announcement (AID+InsuLearn-SMA) in adolescents and young adults with T1D using Automated Insulin Delivery.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Following recruitment and screening, participants will be randomized to one of two sequences during the Hotel Admission: AID+InsuLearn-SMA→AID+CC or AID+CC→AID+InsuLearn-SMA. All participants will be trained on the study equipment, which includes (i) the DiAs smartphone running the Control-IQ algorithm with either the InsuLearn-SMA bolus calculator or the standard carbohydrate counting bolus calculator, and (ii) the Dexcom CGM. All participants will complete 7 days/6 nights run-in At-Home Period using the AID+CC system (Control-IQ with the standard carbohydrate counting bolus calculator). Participants will then undergo a 2-night supervised hotel admission (approximately 48 hours). During this admission, each participant will consume two standardized meals (dinner and breakfast), during which either the InsuLearn-SMA bolus calculator or the standard CC bolus calculator will be used in a randomized order. Two lunches will be offered during the Hotel Admission but not included in the analysis. Following discharge, all participants will complete 7 days/6 nights At-Home Period using the AID+InsuLearn-SMA system before returning the study equipment. The INSPIRE Questionnaire will be administered before and after the Hotel Admission. Additionally, participants will be asked to provide a 2-week CGM data download of their usual care for statistical analysis before randomization and after returning the equipment.

Study Type

Interventional

Enrollment (Actual)

2

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Virginia
      • Charlottesville, Virginia, United States, 22903-2981
        • University of Virginia Center for Diabetes Technology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age ≥14.0 and ≤21 years old at time of consent
  2. HbA1c ≤ 10%.
  3. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year
  4. Having used an insulin pump within the last three months.
  5. Currently using insulin for at least six months
  6. Willingness to use insulin parameters such as carbohydrate ratio and correction factors consistently on their pump in order to dose insulin for meals or corrections
  7. Willingness to switch to a commercially approved insulin (e.g. lispro or aspart or biosimilar approved products) within the study pump as directed by the study team.
  8. Has one or more supportive caregivers or companions living with the participant who are knowledgeable about emergency procedures for treatment of severe hypoglycemia and able to contact emergency services and study staff.
  9. Acceptable forms of contraception for participants of child-bearing potential include hormonal treatments including IUD, abstinence from heterosexual intercourse, vasectomy in partner, barrier methods (e.g. condom or diaphragm).
  10. For females, not currently known to be pregnant or breastfeeding. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
  11. Willingness to use the study InsuLearn system (CGM, pump, and phone) during the study period.
  12. Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial.
  13. Access to internet at home and ability to upload data during the study as needed.
  14. Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol.
  15. Participant is proficient in reading and writing English.

Exclusion Criteria:

  1. History of diabetic ketoacidosis (DKA) in the 12 months prior to enrollment
  2. Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment
  3. Pregnancy or intent to become pregnant during the trial
  4. Currently breastfeeding or planning to breastfeed
  5. Currently being treated for a seizure disorder
  6. Planned surgery during study duration
  7. History of cardiac arrhythmia (except for benign premature atrial contractions and benign premature ventricular contractions which are permitted)
  8. Treatment with any non-insulin glucose-lowering agent (including metformin, GLP-1 agonists, pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals)
  9. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol.
  10. Participation in another interventional trial at the time of enrollment.
  11. Visual impairment/blindness that prevents proper interaction with study equipment
  12. Participant who may have a falsely eligible HbA1c due to medical conditions or blood donations.
  13. Participants in whom the G6 CGM may be inaccurate due to interference.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: AID + InsuLearn-SMA
Participant will use their Automated insulin delivery (AID) system [insulin pump] along with InsuLearn simplified meal announcement bolus calculator
Device: AID + InsuLearn-SMA
Automated insulin delivery (AID) system with InsuLearn simplified meal announcement bolus calculator
Placebo Comparator: Carbohydrate Counting
Participant will use their Automated insulin delivery (AID) system [insulin pump] and their usual carbohydrate counting bolus calculator
Device: AID + CC
Automated insulin delivery (AID) system using usual carbohydrate counting bolus calculator

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
TIR (70-180 mg/dL)
Time Frame: 18 hours
The primary outcome will be the CGM-measured time in range (TIR, 70-180 mg/dL) during the hotel portion.
18 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
TIR (70-180 mg/dL)
Time Frame: 1-week
The primary outcome will be the CGM-measured time in range (TIR, 70-180 mg/dL) during the at-home period.
1-week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Melissa J. Schoelwer

Investigators

  • Principal Investigator: Melissa Schoelwer, MD, University of Virginia School of Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 3, 2026

Primary Completion (Actual)

April 14, 2026

Study Completion (Actual)

April 15, 2026

Study Registration Dates

First Submitted

September 29, 2025

First Submitted That Met QC Criteria

October 6, 2025

First Posted (Actual)

October 8, 2025

Study Record Updates

Last Update Posted (Actual)

May 11, 2026

Last Update Submitted That Met QC Criteria

May 7, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 302850

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 1 Diabetes

Clinical Trials on AID + InsuLearn-SMA

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe